Breaking News
July 17, 2018 - Advanced MRI technique predicts risk of disease progression in MS
July 17, 2018 - Health Tip: Microwave Safely – MedNews
July 17, 2018 - New target for treating heart failure identified
July 17, 2018 - Biodesign fellows simplify heart rhythm monitoring
July 17, 2018 - Study reveals new risk genes for allergic rhinitis
July 17, 2018 - Community college education can increase physician diversity and access to primary care
July 17, 2018 - Inflection Biosciences’ dual mechanism inhibitor shows promise as treatment for CLL
July 17, 2018 - Researchers uncover how cells invite corrupted proteins inside
July 17, 2018 - Studies show HORIBA’s new hematology analyzer improves POCT and care of oncology patients
July 17, 2018 - New website aims to make yoga safer for everyone
July 17, 2018 - Long-term survival worse for black survivors of in-hospital cardiac arrest
July 17, 2018 - Stanford data analyst’s childhood inspires his research: A Q&A
July 17, 2018 - Preventability of hospital readmissions changes over time, study reveals
July 17, 2018 - Nursing notes can help predict if ICU patients will survive
July 17, 2018 - Okayama University research could improve prognosis of diabetic kidney disease
July 17, 2018 - Homogenous BTK occupancy assay used in tirabrutinib clinical studies
July 17, 2018 - Study identifies new genes linked to heart function and development
July 17, 2018 - NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology
July 17, 2018 - Improved methods to measure enterococci concentrations in recreational water
July 17, 2018 - White adolescent boys experiencing early puberty have high risk for substance use
July 17, 2018 - Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 17, 2018 - Roots of leukemia reveal possibility of predicting people at risk
July 17, 2018 - Summer med program embraces low-income students’ potential
July 17, 2018 - New research lays foundation to create standards for RNA sequencing
July 17, 2018 - CRISPR/Cas9 gene editing can cause greater genetic damage than previously thought
July 17, 2018 - Democrats rally against threats to the ACA to block Trump’s Supreme Court nominee
July 17, 2018 - Staggering prices slow insurers’ coverage of CAR-T cancer therapy
July 17, 2018 - How proteins involved in neurodegeneration enter cells
July 17, 2018 - New super-resolution ‘nanoscope’ provides insight into progression of Alzheimer’s disease
July 17, 2018 - FDA Advisory Committee Endorses the Effectiveness and Safety of Single-Dose Tafenoquine for the Radical Cure of P. vivax Malaria
July 17, 2018 - Uncovering the evolutionary history of IBD-associated colorectal cancer
July 17, 2018 - Is nutrition research dependable? Stanford’s John Ioannidis weighs in
July 17, 2018 - New machine learning framework predicts effects of genetic mutations in ‘dark matter’ regions
July 17, 2018 - Plant-based products fail to have positive impact on blood pressure during clinical studies
July 17, 2018 - Electronic system to speed up facial pain diagnosis may improve quality of life and save money
July 17, 2018 - Study delves into the role played by Protein Kinase C in synaptic plasticity
July 17, 2018 - Women Often Unaware of Their Hospital’s Religious Affiliation
July 17, 2018 - New AASM guideline recommends use of actigraphy for sleep disorders
July 17, 2018 - CRISPR editing reduces repetitive behavior in mice with a form of autism
July 17, 2018 - Scientists use magnets to detect cancer
July 17, 2018 - Microfluidic chip to detect sepsis proves successful in clinical study
July 17, 2018 - Research provides better understanding of mechanisms underlying memory storage
July 17, 2018 - A Multi-Modal Approach for the Early Detection of Breast Cancer
July 17, 2018 - Mailing colorectal cancer tests to patients increases screening rates, report researchers
July 17, 2018 - Scientists find possible sources of medicinal and antimicrobial drugs
July 17, 2018 - Molecules formed when the body metabolizes omega-3 fatty acids may inhibit cancer
July 17, 2018 - Efficient communication between hospitals improves patient safety and reduces mortality
July 17, 2018 - Study highlights potential of fetal gene therapy to prevent lethal neurodegenerative disease
July 17, 2018 - For Americans, in Science They Trust
July 17, 2018 - Combating HIV/AIDS | NIH MedlinePlus the Magazine
July 17, 2018 - Study shows minorities widely underrepresented in autism diagnoses
July 17, 2018 - Multigene testing replacing BRCA tests for breast cancer risk | News Center
July 17, 2018 - Pre-clinical pilot study shows promising results of ‘concussion pill’
July 17, 2018 - Researchers reduce size of tumors in mice by artificially activating the brain’s reward system
July 17, 2018 - New study documents symptoms of people before they acquire multiple sclerosis
July 17, 2018 - Researchers discover why CRISPR gene editing sometimes fails
July 17, 2018 - New finding may hold key to better understand the complexities of neurological disorders
July 17, 2018 - The Current issue of “The view from here” is concerned with Novel Targets.
July 17, 2018 - Fighting the Flu with a Universal Vaccine
July 17, 2018 - Key social reward circuit in the brain impaired in kids with autism | News Center
July 17, 2018 - Insight into causes, types and treatment of aphasia
July 16, 2018 - Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
July 16, 2018 - NSAIDs shown to have causal role in cardiovascular risk of patients with osteoarthritis
July 16, 2018 - PET scan tracer predicts success of cancer ‘vaccine’ | News Center
July 16, 2018 - Parents struggle with what to do when their child has headache, shows study
July 16, 2018 - Outrageous or overblown? HHS announces another round of ACA navigator funding cuts
July 16, 2018 - Weight loss surgery may impact individual’s risk of developing cancer, shows study
July 16, 2018 - Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
July 16, 2018 - Restoring epigenetic balance reinstates memory in flies with Alzheimer’s disease symptoms
July 16, 2018 - Magnetized wire could be used to detect cancer in people | News Center
July 16, 2018 - Non-surgical management found to be feasible option for penetrating kidney trauma
July 16, 2018 - California clinic screens asylum seekers for honesty
July 16, 2018 - FDA Approves Xtandi (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
July 16, 2018 - Can nanotechnology help treat Alzheimer’s?
July 16, 2018 - Researchers identify protein essential for making stem cells | News Center
July 16, 2018 - Severe childhood infections linked with lower school achievement in adolescence
July 16, 2018 - Radiologist discusses causes, treatments of varicose veins
July 16, 2018 - Researchers develop nanostructured surface to accelerate wound healing after dental implants
July 16, 2018 - New non-invasive procedure to reposition kidney stones could benefit astronauts
July 16, 2018 - Attending Surgeon Influences Genetic Testing in Breast Cancer
Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s

Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s

image_pdfDownload PDFimage_print

Action Points

  • Upfront treatment with the antibody-drug conjugate brentuximab vedotin (Adcetris) led to significantly better progression-free survival for patients with newly diagnosed advanced Hodgkin lymphoma.
  • The addition of brentuximab to chemotherapy increased rates of neutropenia and peripheral neuropathy, which was manageable in most cases.

ATLANTA — Upfront treatment with the antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) led to significantly better progression-free survival (PFS) for patients with newly diagnosed advanced Hodgkin lymphoma, investigators reported here.

Patients who received the ADC, in addition to standard first-line chemotherapy, had a 2-year PFS of 82.1% versus 77.2% for chemotherapy alone. An interim analysis of overall survival (OS) showed a trend in favor of the brentuximab regimen, but the difference did not achieve statistical significance, according to James M. Connors, MD, of the British Columbia Cancer Agency in Vancouver, and colleagues.

The addition of brentuximab to chemotherapy increased rates of neutropenia and peripheral neuropathy, which was manageable in most cases, Connors said during a presentation at the American Society of Hematology meeting. The study was published simultaneously in the New England Journal of Medicine.

The trial also provided support for omitting bleomycin from chemotherapy when brentuximab is used.

“The (brentuximab) regimen is associated with more myelotoxicity — which can be ameliorated with prophylactic G-CSF — and neurotoxicity — which is largely reversible) than ABVD but substantially less pulmonary toxicity and appears to be more effective for the frontline treatment of advanced-stage classic Hodgkin’s lymphoma,” Connors’ group wrote.

Authors of an accompanying NEJM editorial cautioned that follow-up time for the study was too brief to rule out the possibility of late side effects with brentuximab regimen. However, they gave tentative support for upfront use of the ADC.

“It appears that the addition of brentuximab vedotin to AVD combination chemotherapy … merits consideration as first-line treatment for advanced Hodgkin’s lymphoma,” wrote Daniel Longo, MD, and Vincent T. DeVita Jr., MD, both of Yale Cancer Center in New Haven, Connecticut. “Although the follow-up time has been relatively short the (ADC combination) appears to be more effective than ABVD (and is unlikely to be less effective) and is associated with fewer, more treatable toxicities.”

Outcomes for advanced Hodgkin’s lymphoma improved substantially over the past 50 years, especially after the introduction of ABVD combination chemotherapy (doxorubicin-bleomycin-vinblastine-dacarbazine) more than 40 years ago. However, 25% to 30% of patients have refractory disease or relapse after initial treatment with ABVD, Connors’ group noted. Moreover, bleomycin can cause unpredictable and potentially fatal pulmonary toxicity.

Brentuximab vedotin consists of a monoclonal antibody that targets the CD30 surface antigen — expressed by Reed-Sternberg cells in classic Hodgkin’s lymphoma — to the microtubule-disrupting agent monomethyl auristatin. The ADC has FDA approval as treatment for classic Hodgkin’s lymphoma that does not respond, or recurs after stem-cell transplantation or failure of at least two multiagent chemotherapy regimens. The drug also has approval as posttransplant consolidation therapy for high-risk patients.

The decision to include bleomycin in chemotherapy (ABVD) remains controversial, both in terms of efficacy and added toxicity, particularly pulmonary toxicity. In a phase I trial of frontline therapy for advanced Hodgkin’s lymphoma, brentuximab vedotin combined with AVD chemotherapy led to complete responses in 24 of 25 patients, a 5-year failure-free survival of 92%, and OS of 100%.

Connors presented results from a phase III randomized trials to compare brentuximab vedotin plus AVD chemotherapy with standard ABVD chemotherapy in 1,334 patients with untreated stage III or IV classic Hodgkin’s lymphoma. The trial had a primary endpoint of modified PFS — the time to disease progression, death, or non-complete response and use of subsequent anticancer therapy, adjudicated by an independent review committee.

The study population had a median age of 36, and men accounted for 58% of the patients. Two-thirds of the patients had stage IV disease, 62% had extranodal involvement at diagnosis, and 58% had B symptoms (such as night sweats, weight loss, and fever).

After a median follow-up of 25 months, the brentuximab regimen had resulted in a 23% reduction in the hazard for the primary endpoint (95% CI 0.60-0.98, P=0.03). The preliminary survival analysis showed that 28 patients ion the brentuximab arm died versus 39 in the ABVD arm, which translated into a nonsignificant 28% reduction in the hazard ratio in favor of brentuximab (95% CI 0.44-1.17, P=0.19).

With respect to safety, the most common adverse event in both groups was neutropenia, which occurred in 58% of the brentuximab arm and 45% of the ABVD arm. Febrile neutropenia occurred in 19% and 8% of the brentuximab and ABVD groups, respectively. In the brentuximab arm, febrile neutropenia occurred less in of 83 patients who received prophylactic G-CSF (11% vs 21%). Connors said 1% of patients in each group discontinued because of febrile neutropenia.

Other common adverse events (any grade) were infection (55% vs 50%), constipation (42% with brentuximab, 37% with ABVD), vomiting (33% vs 28%), fatigue (32% in both groups), peripheral sensory neuropathy (29% vs 17%), diarrhea (27% vs 18%), pyrexia (26% vs 13%), abdominal pain (21% vs 10%), and stomatitis (21% vs 16%). Neutropenia (54% vs 39%) was the only grade 3 adverse event that occurred in more than 5% of patients in either group.

Pulmonary toxicity occurred in 2% and 7% of the brentuximab and ABVD groups, respectively, including grade ≥3 pulmonary toxicity in 1% and 3%.

The study was supported by Seattle Genetics and Millennium Pharmaceuticals.

Connors disclosed relevant relationships with Janssen, Genentech, NanoString Technologies, Merck, F Hoffmann-La Roche, Cephalon, Seattle Genetics, Bayer Healthcare, Bristol-Myers Squibb, Takeda, Amgen, and Eli Lilly.

Longo disclosed serving as deputy editor of the New England Journal of Medicine. DeVita disclosed no relevant relationships with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


last updated

Tagged with:

About author

Related Articles